-transparent.png){kind=logo}
Twenty-five patients with previously untreated adenocarcinoma of the ovary (International Federation of Gynecology and Obstetrics, stages II, III, and IV) were placed on a six-drug trial (CHAMP-5) for 18 months. This trial consisted of 28-day cycles of hexamethylmelamine, doxorubicin, and cisplatin alternating with hexamethylmelamine, cyclophosphamide, methotrexate, and 5-FU. After a minimum follow-up of 31 months, 14 (56%) of the 25 evaluable patients achieved complete or partial response and nine (36%) achieved complete pathologic response. Although CHAMP-5 is effective in the treatment of ovarian cancer, the results in these patients are not substantially different from those achieved with hexamethylmelamine, doxorubicin, and cisplatin alone.
M W Pasmantier, and
M Coleman, and
R T Silver, and
W P Ballard
May 1982,
Cancer treatment reports,
M W Pasmantier, and
M Coleman, and
R T Silver, and
W P Ballard
October 1990,
American journal of clinical oncology,
M W Pasmantier, and
M Coleman, and
R T Silver, and
W P Ballard
September 1989,
European journal of cancer & clinical oncology,
M W Pasmantier, and
M Coleman, and
R T Silver, and
W P Ballard
January 1981,
Cancer treatment reports,
M W Pasmantier, and
M Coleman, and
R T Silver, and
W P Ballard
January 1997,
European journal of gynaecological oncology,
M W Pasmantier, and
M Coleman, and
R T Silver, and
W P Ballard
November 1985,
Cancer treatment reports,
M W Pasmantier, and
M Coleman, and
R T Silver, and
W P Ballard
December 1984,
Cancer treatment reports,
M W Pasmantier, and
M Coleman, and
R T Silver, and
W P Ballard
October 1985,
Gynecologic oncology,
M W Pasmantier, and
M Coleman, and
R T Silver, and
W P Ballard
January 1981,
Cancer treatment reports,
M W Pasmantier, and
M Coleman, and
R T Silver, and
W P Ballard
April 1993,
Obstetrics and gynecology,
